MLTX
NASDAQMoonLake Immunotherapeutics
News · 26 weeks46+20%
2026-03-012026-08-23
Mix3090d
- Insider14(47%)
- SEC Filings10(33%)
- Other4(13%)
- Offering2(7%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by MoonLake ImmunotherapeuticsSCHEDULE 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
- SECSEC Form S-8 filed by MoonLake ImmunotherapeuticsS-8 - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECSEC Form S-3ASR filed by MoonLake ImmunotherapeuticsS-3ASR - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECSEC Form 10-Q filed by MoonLake Immunotherapeutics10-Q - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECMoonLake Immunotherapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
- PRMoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial ResultsPhase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and significant responses were observed across key secondary endpoints, including ACR20 (66.5%), MDA (41.2%) and PASI90 (61%), supporting the broad multidomain efficacy profile of sonelokimab in psoriatic arthritisMeaningful and statistically significant improvements were seen across patient-reported outcomes and physical function measures, including HAQ-DI and SF-36 PCSBlinded safety analysis suggests a profile consistent with previous studies and no new safety signals were identified
- INSIDERChief Scientific Officer Reich Kristian sold $22,000 worth of Class A ordinary shares (1,100 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERChief Scientific Officer Reich Kristian sold $1,049,960 worth of Class A ordinary shares (52,448 units at $20.02) as part of a pre-agreed trading plan (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERChief Scientific Officer Reich Kristian sold $877,933 worth of Class A ordinary shares (43,700 units at $20.09) as part of a pre-agreed trading plan (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERChief Scientific Officer Reich Kristian sold $322,261 worth of Class A ordinary shares (16,105 units at $20.01) as part of a pre-agreed trading plan (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERChief Executive Officer Santos Da Silva Jorge sold $2,046,205 worth of Class A ordinary shares (102,225 units at $20.02) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 2,774,893 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERChief Executive Officer Santos Da Silva Jorge sold $956,933 worth of Class A ordinary shares (47,775 units at $20.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 2,877,118 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by MoonLake ImmunotherapeuticsSCHEDULE 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)
- SECMoonLake Immunotherapeutics filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECSEC Form 424B5 filed by MoonLake Immunotherapeutics424B5 - MoonLake Immunotherapeutics (0001821586) (Filer)
- PRMoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public OfferingZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced the pricing of an underwritten public offering of 9,000,000 Class A ordinary shares at a public offering price per share of $20.00 and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase up to 1,000,000 Class A ordinary shares at a public offering price per pre-funded warrant of $19.9999, which equals the public offering price per Class A ordinary share less the $0.0001 per share exercise price of each pre-funded wa
- INSIDERChief Financial Officer Bodenstedt Matthias sold $862,205 worth of Class A ordinary shares (39,120 units at $22.04) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,115,435 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- PRMoonLake Immunotherapeutics Announces Proposed Public OfferingZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced a proposed public offering of $150 million of its Class A ordinary shares and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase Class A ordinary shares. In addition, MoonLake is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $22.5 million of its Class A ordinary shares offered in the proposed offering at the public offering price, less the under
- SECSEC Form 424B5 filed by MoonLake Immunotherapeutics424B5 - MoonLake Immunotherapeutics (0001821586) (Filer)
- INSIDERSEC Form 4 filed by Director Bvf Partners L P/Il4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SECMoonLake Immunotherapeutics filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
- PRMoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with consistent responses that are higher than those observed in trials of competing agents at the end of their respective parental trialsNamely, ~67% of patients treated with SLK achieved HiSCR75 at the one-year mark, with more than one quarter of patients achieving inflammatory remission (IHS4-100), and around one third reaching HiSCR100Patients treated with SLK likewise showed substantial improvement in HiSQOL at Week 52, with a mean score difference between end of trial and baseline of
- INSIDERSEC Form 4 filed by Director Phillips Andrew John4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERChief Financial Officer Bodenstedt Matthias sold $351,576 worth of Class A ordinary shares (17,876 units at $19.67) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,154,555 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 4 filed by Director Loy Spike4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
MLTX FAQ
7 questionsWhat does MoonLake Immunotherapeutics do?
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.Where does MLTX stock trade?
MoonLake Immunotherapeutics (MLTX) is listed on NASDAQ.What sector and industry is MLTX in?
MoonLake Immunotherapeutics operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MoonLake Immunotherapeutics go public?
MoonLake Immunotherapeutics (MLTX) completed its IPO in 2020.What are analysts saying about MLTX?
MoonLake Immunotherapeutics has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform with a $2400.00 price target on 2026-03-23.What companies are similar to MLTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MLTX side-by-side with any of them on Quantisnow.How can I track MLTX on Quantisnow?
Quantisnow aggregates MoonLake Immunotherapeutics's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MLTX to receive live email and push alerts on every new disclosure.